Clinical Trial Detail

NCT ID NCT02690948
Title Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Anne Chang
Indications

basal cell carcinoma

Therapies

Pembrolizumab + Vismodegib

Pembrolizumab

Age Groups: adult

No variant requirements are available.